News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zonagen (ZONA) Receives IRB Approval to Commence Phase III Study Of Androxal(TM) For The Treatment Of Testosterone Deficiency



1/9/2006 4:27:19 PM

Zonagen, Inc. (Nasdaq:ZONA)(PCX:ZONA), a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders, today announced that the Company has received Investigational Review Board (IRB) approval for the start of its Phase III study of Androxal(TM), a once-a-day oral therapy for the treatment of testosterone deficiency resulting from a condition known as secondary hypogonadism. The 200 patient trial will be conducted in the U.S. under an existing U.S. Investigational New Drug application and will enroll patients at up to 20 clinical sites.

Read at BioSpace.com

Related News

comments powered by Disqus
Zonagen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES